Senior Peer Alliance for Rural Research On Wellness (SPARROW)

Case Management and Problem Solving Therapy for Depressed Older Adults

Dr. Brooke Hollister, Ph.D. from the department of Social and Behavioral Sciences at the University of California, San Francisco is conducting a study comparing two types of interventions for treating depression in rural older adults.

Study Overview

• Status: Completed
• Conditions: MDD
• Intervention / Treatment: Behavioral: CM-PST; Behavioral: SG-PST

Detailed Description

If you are eligible to participate in the study after completing the screening assessment, and if you choose to continue on, we will randomize you (like a flip of a coin) to receive either 12 weeks of case management combined with problem solving therapy (CM-PST) with a social worker or 12 weeks of self-guided problem solving therapy (SG-PST) with support from a senior peer counselor.

As part of your participation in the study you will participate in three 1.5 hour assessment interviews of psychological and neuropsychological functioning (similar to your screening assessment) prior to your first week of treatment (baseline), two weeks after your final session (week 14), and three months after your final session (week 24). Additionally, you will participate in three shorter assessment interviews of psychological functioning, which will be conducted at weeks 3 and 6. These assessments will take approximately 30-45 minutes.

• Study Type: Interventional
• Enrollment (Actual): 105
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Sonora, California, United States, 95370
      • Catholic Charities Motherlode Office- Sonora

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Residence in rural Tuolumne, Calaveras, San Joaquin or Stanislaus Counties;
• Diagnosis: Major depression, unipolar (by SCID ascertained DSM-IV criteria);
• Severity of depression: A PHQ-9>10 or a 24-Item HDRS>19;
• Need for social services: CANE score> 2, i.e. at least one unmet need;

Exclusion Criteria:

• Psychotic depression by SCID-IV, i.e., presence of delusions;
• High suicide risk, i.e. intent or plan to attempt suicide in near future;
• Presence of any Axis I psychiatric disorder or substance abuse other than unipolar major depression;
• Axis II diagnosis of antisocial personality (by SCID-P and DSM-IV);
• History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (including bipolar disorder, hypomania, and dysthymia);
• Dementia: MMSE below 24 or clinical diagnosis of dementia by DSM-IV;
• Acute/severe medical illness (delirium, metastatic cancer, de-compensated cardiac, liver or kidney failure, stroke or myocardial infarction) 3 months prior to entry; or use of drugs causing depression, (steroids, reserpine, alphamethyl-dopa, tamoxiphen, vincristine);
• Inability to perform any of the ADLs (MAI: ADL subscale) even with assistance (walking with a cane is not an exclusion criterion)
• Inability to speak English;
• Aphasia interfering with communication;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CM-PST; If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.	Behavioral: CM-PST
Experimental: SG-PST; If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.	Behavioral: SG-PST

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hamilton Rating Scale for Depression (HRSD)	A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.	Baseline
Hamilton Rating Scale for Depression (HRSD)	A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.	Week 3
Hamilton Rating Scale for Depression (HRSD)	A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.	Week 6
Hamilton Rating Scale for Depression (HRSD)	A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.	Week 12
WHO Disability Assessment Schedule 2.0 (WHODAS-II)	Generic assessment instrument for health and disability	Week 0
WHO Disability Assessment Schedule 2.0 (WHODAS-II)	Generic assessment instrument for health and disability	Week 3
WHO Disability Assessment Schedule 2.0 (WHODAS-II)	Generic assessment instrument for health and disability	Week 6
WHO Disability Assessment Schedule 2.0 (WHODAS-II)	Generic assessment instrument for health and disability	Week 12

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Investigators: Principal Investigator: Brooke Hollister, Ph.D., University of California, San Francisco; Principal Investigator: Patricia Arean, Ph.D., University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2013
• Primary Completion (Actual): August 1, 2018
• Study Completion (Actual): March 31, 2019

Study Registration Dates

• First Submitted: July 29, 2013
• First Submitted That Met QC Criteria: July 29, 2013
• First Posted (Estimate): August 1, 2013

Study Record Updates

• Last Update Posted (Actual): July 31, 2019
• Last Update Submitted That Met QC Criteria: July 30, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: R01AG043584-01A1 (U.S. NIH Grant/Contract)